Pharmaceutical Research

, Volume 15, Issue 1, pp 31–38 | Cite as

Design, Synthesis, and Biological Evaluation of Spider Toxin (Argiotoxin-636) Analogs as NMDA Receptor Antagonists

  • Scott T. Moe
  • Daryl L. Smith
  • Yongwei (Eric) Chien
  • Joanna L. Raszkiewicz
  • Linda D. Artman
  • Alan L. Mueller


Purpose. Twelve synthetic spider toxin analogs were prepared in an effort to better understand the structure-activity relationships of the polyamine portion of argiotoxin-636 (Arg-636), a noncompetitive NMDA receptor (NMDAR) antagonist.

Methods. The l,13-diamino-4,8-diazatridecane portion of the side chain of Arg-636 was systematically modified in an effort to further our knowledge of the structural requirements for the alkyl linker spacing between the amine nitrogens. Systematic isosteric replacement of each of the amine nitrogens in the polyamine moiety with either oxygen or carbon provided a series of compounds which were evaluated in vitro for NMDAR antagonist activity.

Results. One-half of the heteroatoms found in Arg-636 were removed to provide analogs which maintained in vitro potency below 1 μM. However, these simplified analogs produced similar or more pronounced effects on the cardiovascular system than Arg-636 in vivo.

Conclusions. In this set of analogs, a minimum of three basic nitrogens in the side chain was required for maximum potency as NMDAR antagonists. Isosteric nitrogen substitutions in the polyamine chain reduced the in vitro potency of these analogs. An analog binding-conformation model was proposed to rationalize the inactivity of these isosterically substituted analogs.

glutamate NMDA N-methyl-D-aspartate Argiotoxin-636 Arg-636 polyamine spider toxins Araxin compounds ischemic stroke 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    B. C. Van Wagenen, E. G. DelMar, S. T. Moe, S. M. Shimizu, D. L. Smith, R. M. Barmore, R. Trovato, J. L. Rhodes, A. P. Miaullis, M. F. Balandrin, L. D. Artman, N. Alasti, and A. L. Mueller. 209th American Chemical Society National Meeting, MEDI 134, April 2–6, 1995.Google Scholar
  2. 2.
    A. L. Mueller, B. C. Van Wagenen, E. G. Delmar, M. F. Balandrin, S. T. Moe, and L. D. Artman. PCT Intl. Appl. WO 95/21612, August 17, 1995. Chem. Abstr. 123(23): P 306618t (1995). U.S. Pat. Appl. 14,813, February 8, 1994.Google Scholar
  3. 3.
    A. L. Mueller, L. D. Artman, Y. Chien, J. L. Raszkiewicz, N. Alasti, E. G. DelMar, B. C. Van Wagenen, S. T. Moe, M. F. Balandrin, D. L. Smith, S. M. Shimizu, J. L. Rhodes, R. Trovato, and R. M. Barmore. Keystone Symposia on Molecular and Cellular Biology: Ion Channels as Theraputic Targets, Tamarron, CO, February 4–10, 1996.Google Scholar
  4. 4.
    N. A. Saccomano, R. A. Volkmann, H. Jackson, and T. N. Parks. Annu. Rep. Med. Chem. 24:287–293 (1989).Google Scholar
  5. 5.
    D. L. Smith, S. T. Moe, L. D. Artman, and A. L. Mueller. Joint 50th Northwest/12th Rocky Mountain Regional American Chemical Society Meeting, No. 221, June 14–16 (1995).Google Scholar
  6. 6.
    S. T. Moe, D. L. Smith, L. D. Artman, and A. L. Mueller. Joint 50th Northwest/12th Rocky Mountain Regional American Chemical Society Meeting, No. 222, June 14–16 (1995).Google Scholar
  7. 7.
    A. L. Mueller, R. Roeloffs, and H, Jackson. In G. A. Cordell (Ed.), The Alkaloids, Academic Press, NY, 1995, Vol. 46, pp. 63–94.Google Scholar
  8. 8.
    A. Schäfer, A. Benz, W. Fiedler, A. Guggisberg, S. Beinz, and M. Hesse. In G. A. Cordell and A. Brossi (Eds.), The Alkaloids: Chemistry and Pharmacology, Vol. 45, Academic Press, NY, 1993, pp. 1–125.Google Scholar
  9. 9.
    E. V. Grishin, T. M. Volkova, A. S. Arseniev, O. S. Reshetova, and V. V. Onopreinko. Bioorg. Khim. 12:1121–1124 (1986).Google Scholar
  10. 10.
    A. Bateman, P. Boden, A. Dell, I. R. Duce, D. L. J. Quicke, and P. N. R. Usherwood. Brain Res. 339:237–244 (1989).Google Scholar
  11. 11.
    T. Budd, P. Clinton, A. Dell, I. R. Duce, S. J. Johnson, D. L. J. Quicke, G. W. Taylor, P. N. R. Usherwood, and G. Usoh. Brain Res. 448:30–39 (1988).Google Scholar
  12. 12.
    J. E. Watkins and R. H. Evans. Annu. Rev. Pharmacol. Toxicol. 21:165–204 (1981).Google Scholar
  13. 13.
    A. C. Foster and G. E. Fagg. Brain Res. Rev. 1:103–104 (1984).Google Scholar
  14. 14.
    A. L. Mueller, B. C. Albenzi, A. H. Ganong, L. S. Reynolds, and H. Jackson. Synapse 9:244–250 (1991).Google Scholar
  15. 15.
    R. W. Ransom and N. L. Stec. J. Neurochem. 51:830 (1988).Google Scholar
  16. 16.
    D. W. Choi. Neuron 1:623–634 (1988).Google Scholar
  17. 17.
    A. B. MacDermott, M. L. Mayer, G. L. Westbrook, S. J. Smith, and J. L. Barker. Nature 321:519–522 (1986).Google Scholar
  18. 18.
    F. A. Schanne, A. B. Kane, E. E. Young, and J. L. Farber. Science 206:700–702 (1979).Google Scholar
  19. 19.
    B. S. Meldrum and A. G. Chapman. In G. L. Collingridge and J. C. Watkins (Eds.), The NMDA Receptor, 2nd ed., Oxford University Press, NY, 1994, pp. 457–468.Google Scholar
  20. 20.
    P. L. Feldman, O. W. Griffith, and D. J. Stuehr. Chem. Eng. News 71:26–38 (1993).Google Scholar
  21. 21.
    P. A. Krapcho and C. S. Kuell. Synth. Commun. 20:2559–2564 (1990).Google Scholar
  22. 22.
    T. N. Parks, L. D. Artman, N. Alasti, and E. F. Nemeth. Brain Res. 552:13–22 (1991).Google Scholar
  23. 23.
    K. Williams, C. Romano, and P. B. Molinoff. Molec. Pharmacol. 36:575–581 (1989).Google Scholar
  24. 24.
    O. H. Lowry, N. H. Rosenbrough, A. C. Farr, and R. J. Randall. J. Biol. Chem. 193:265–275 (1951).Google Scholar
  25. 25.
    T. L. Shih, J. R. Sanchez, and H. Mrozik. Tetrahedron Lett. 28:6015–6018 (1987).Google Scholar
  26. 26.
    M. E. Adams, R. L. Carney, F. E. Enderlin, E. T. Fu, M. A. Jarema, J. P. Li, C. A. Miller, D. A. Schooley, M. J. Shapiro, and V. J. Venema. Biochem. Biophys. Res. Commun. 148:678–683 (1987).Google Scholar
  27. 27.
    É. A. Elin, B. F. de Masedo, V. V. Onoprienko, N. E. Osokina, and O. B. Tikhomirova. Bioorg. Khim. 14:704–706 (1988) (translation by Plenum Publishing Co., 1989).Google Scholar
  28. 28.
    V. J. Jasys, P. R. Kelbaugh, D. M. Nason, D. Phillips, N. A. Saccomano, and R. A. Volkmann. Tetrahedron Lett. 29:6223–6226 (1988).Google Scholar
  29. 29.
    S.-K. Choi and K. Nakanishi. Tetrahedron 49:5777–5790 (1993).Google Scholar
  30. 30.
    N. Anis, S. Sherby, R. Goodnow, Jr., M. Niwa, K. Konno, T. Kallimopoloulos, R. Bukownik, K. Nakanishi, P. Usherwood, A. Eldefrawi, and M. Eldefrawi. J. Pharmacol. Exptl. Therap. 254:764–773 (1990).Google Scholar

Copyright information

© Plenum Publishing Corporation 1998

Authors and Affiliations

  • Scott T. Moe
    • 1
  • Daryl L. Smith
    • 1
  • Yongwei (Eric) Chien
    • 2
  • Joanna L. Raszkiewicz
    • 2
  • Linda D. Artman
    • 2
  • Alan L. Mueller
    • 2
  1. 1.Medicinal Chemistry andPharmacology Groups NPS Pharmaceuticals, Inc.Salt Lake City
  2. 2.Pharmacology GroupsNPS Pharmaceuticals, Inc.Salt Lake City

Personalised recommendations